PRP Shows >90% Tumor Inhibition in Pancreatic Cancer Models, Trial Accelerated
PPCB sits 25% above its 52-week low of $0.95 on light trading volume (0.2× avg).
Summary
Propanc's lead candidate PRP achieved >90% tumor growth inhibition and a >2.5-fold survival extension in aggressive pancreatic cancer models, surpassing prior >85% inhibition data. The company is accelerating its Phase 1b first-in-human trial, with a clinical trial application expected in Australia in the coming months. This follows a recent $5M buyback program and insider share issuance, signaling management confidence despite a tight cash position. The data strengthens the case for PRP's differentiated mechanism targeting cancer stem cells and the tumor microenvironment. Upcoming milestones include GMP manufacturing targeted for late 2026 and trial initiation.
At the time of this announcement, PPCB was trading at $1.19 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $4.1M. The 52-week trading range was $0.95 to $270.25. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: GlobeNewswire.